{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005357","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.069324+00:00","generated_at":"2026-06-24T04:25:11.566489+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aligos reports Q2 net loss $19.9M ($0.47), cash $159.3M, advances HBV/siRNA programs","bullets":["Net loss $19.9M ($0.47/share) vs $29.8M ($0.79) in Q2 2021.","Cash & investments $159.3M at June 30, 2022 (down from $205.8M at Dec 31, 2021); funds ops into H1 2024.","R&D expenses decreased to $16.5M from $24.6M YoY, reflecting STOPS/ASO wind-down.","Completed enrollment in multiple CAM-2 and NASH Phase 1 cohorts; on track to file CTA for siRNA ALG-125755 in Q3 2022.","COVID-19 3CL PI ALG-097558 shows only 3-fold EC50 shift against resistant mutant vs >50-fold for nirmatrelvir."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005357","json":"https://secwatch.observer/filing/0001171843-22-005357.json","markdown":"https://secwatch.observer/filing/0001171843-22-005357.md","text":"https://secwatch.observer/filing/0001171843-22-005357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/0001171843-22-005357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184322005357/f8k_080322.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:25:11.566489+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}